Novabiosis Inc. and Promethera Therapeutics Joint Release

Novabiosis Inc. and Promethera Therapeutics Joint Release

Novabiosis Inc. & Promethera Therapuetics
Joint Release

RESEARCH TRIANGLE PARK, NC. and MONT-SAINT-GUIBERT, BELGIUM – October 6th 2021 — Promethera Therapeutics SA, a pioneer in cell therapies for treatment of severe liver diseases, has divested certain assets of their US subsidiary, Promethera Biosciences, LLC.

Novabiosis, Inc. a new organization led by former Promethera Biosciences, LLC VP Matthew Shipton, has acquired the assets of Promethera’s human cell and tissue-based research products business, formerly known as Novabiosis.

“In 2017, Promethera formed Novabiosis as a separate division to supply high quality isolated primary human cells to the research community.  While successful, Novabiosis plan for future growth and development and Promethera Therapeutics new vision, justified this deal” said Mr. Shipton former leader of the Novabiosis division. Mr. Shipton, who will serve as President of Novabiosis, Inc. added “This is great opportunity for our team to carry on the work we did under Promethera, growing the Novabiosis brand. We have a great team of investors behind us, with a shared vision for Novabiosis, Inc.”

Novabiosis, Inc will operate out of The Lab, a facility in Research Triangle Park, NC. 

“We are happy of having closed this strategic deal that allows Promethera to both secure its liver sourcing from the US and decrease significantly the previous US costs, it is another successful step in our plan” explained Professor Etienne Sokal, Founder, CEO and Chairman of the Board of Promethera.

Terms of deal were not disclosed.




Promethera® Therapeutics is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. The lead clinical program is derived from the patented cell technology platform HepaStem®. Promethera®, HepaStem®, H2stem®, are all registered trademarks of the PROMETHERA Group.


NOVABIOSIS, INC is the premier provider of high quality, well characterized, primary human cell and tissue-based products to the academic, biotech, and pharmaceutical research communities. Novabiosis, Inc also sources whole non-transplantable organs and tissues, coordinating their placement with researchers who use them for research and development in support of unmet medical needs.